Feed Articles

3 biotech stocks to watch in 2025

The biotechnology sector faced a challenging environment in 2024. Yet there are companies that many analysts believe could be attractive investments in 2025. Which companies are they?

Biotech: High risk, high reward

The biotech sector is known for its volatility. In 2024, it has been impacted by high interest rates and a volatile healthcare environment. Still, the right investment can yield high profits, especially through breakthrough drugs or research successes.

Avadel Pharmaceuticals $AVDL: Opportunity in a down stock

Avadel Pharmaceuticals specializes in the treatment of narcolepsy through its core product Lumryz. The company achieved $50 million in revenue in the last quarter of 2024, representing a year-over-year increase of more than 150%. Still, the stock fell significantly due to a lower-than-expected outlook for 2025 ($240-260 million).

Avadel faces a challenge in the form of patient churn, but is working to increase Lumryz adoption. At the same time, it continues to progress through Phase 3 clinical trials and has over $70 million in cash, giving it room to improve. For adventurous investors who believe in long-term growth, the decline of more than 48% over the past year may be a buying opportunity.

Sana Biotechnology $SANA: Revolutionizing the treatment of type 1 diabetes

Sana Biotechnology is a gene and cell therapy company whose stock is down 48.5% in 2024. Sana recently released breakthrough data from a clinical trial focused on allogeneic transplantation - the transfer of healthy donor cells without the need for immunosuppressive drugs. This approach could revolutionize the treatment of type 1 diabetes and other diseases.

Following the news, Sana's stock more than doubled in value, rising 65% in the past month. Analysts estimate growth of up to 350% with a target price of $14.25, making the company an attractive investment with high potential.

ADMA Biologics $ADMA: Rapid revenue and earnings growth

ADMA Biologics has seen significant success in 2024 due to the commercialization of its products. Third-quarter revenue grew 78% to $120 million, while net income rose 1,300% to nearly $36 million.

The company expects further revenue growth in 2025 to over $485 million and in 2026 to over $600 million. It plans to reach $1 billion in annual sales by 2030. Although ADMA stock is up 228% over the past year, analysts still see potential for further growth.

Disclaimer: You will find a lot of inspiration on Bulios, but stock selection and portfolio construction is up to you, so always do a thorough analysis of your own.

Source: marketbeat

A community member's personal view, not investment advice. Community Guidelines

Follow Bulios on Google News

Be among the first to discover new analyses, news and market moves.

Follow

Recommended articles

Read more

Expensive oil was supposed to sink them; these 3 cruise lines instead report records and expect further growth

Oil this year soared to $138 per barrel, and cruise ships, which burn hundreds of thousands of tons of it annually, were supposed to be the first to suffer. Instead, all three largest cruise operators raised their profit outlooks, yet for a dollar of profit the market pays almost twice as much for…

MC
Milan Charvat
· 6h
Read more
BLACK

Man with Parkinson's stood up and walked away after an injection. The drugmaker's stock still fell 20%

A man with Parkinson's who couldn't get up from a chair walked out through the door on his own after a year of treatment with his own cells. The company behind the treatment raised $140.6 million in its IPO, and three weeks later its stock is 20% cheaper, even though there hasn't been a single…

MC
Milan Charvat
· 10h
Read more
BLACK

Dividends Above 10%? No Problem for These Stocks

A yield of over 15% a year sounds almost unbelievable in the stock market, yet several established US-listed securities are offering just that today. Mortgage REITs and leveraged bond funds earn money from the difference between the yield on mortgages or bonds and the cost of short-term financing,…

KJ
Kryštof Jáně
· 13h

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy